TriSalus Appoints David B. Patience as CFO Amid Transition
Investor - People | May 30, 2025 | Tullis-Dickerson & Co Inc
TriSalus Life Sciences, a company focusing on oncology innovations, has announced a change in its financial leadership. Effective July 1, 2025, David B. Patience will become the new Chief Financial Officer, stepping in after the resignation of James E. Young, the current CFO, who is stepping down for personal reasons. During the transition, Dan Giordano, Vice President of Finance, will act as interim CFO. David Patience brings substantial experience from his previous roles, including a tenure as CFO at Accelerate Diagnostics. TriSalus, which is at the forefront of integrating novel drug delivery technologies with standard cancer treatments, looks to leverage Patience's expertise in driving its growth phase and exploring new strategic opportunities. Meanwhile, the company continues to advance its clinical trials and seeks partnerships to further develop its proprietary technologies and treatments, including its investigational immunotherapy candidate, nelitolimod.
Sectors
- Healthcare & Life Sciences
- Financial Services
Geography
- United States – TriSalus Life Sciences is based in Denver, Colorado, U.S., and its activities and leadership changes are relevant to the U.S. market.
Industry
- Healthcare & Life Sciences – TriSalus Life Sciences operates within the healthcare sector, focusing on innovative oncology treatments and technologies.
- Financial Services – David B. Patience's background in financial leadership and investment banking is central to his new role as CFO at TriSalus.
Financials
Participants
| Name | Role | Type | Description |
|---|---|---|---|
| TriSalus Life Sciences, Inc. | Target Company | Company | An oncology-focused medical technology company integrating novel delivery technology with therapies. |
| David B. Patience | Incoming Chief Financial Officer | Person | Appointed as new CFO of TriSalus Life Sciences, effective July 1, 2025. |
| James E. Young | Outgoing Chief Financial Officer | Person | Stepping down as CFO for personal reasons effective May 30, 2025. |
| Dan Giordano | Acting Chief Financial Officer | Person | Vice President of Finance serving as interim CFO during the transition. |
| Tullis-Dickerson & Co Inc. | Private Equity Firm | Company | The PE firm associated with the ongoing financial and leadership strategies at TriSalus. |
| Accelerate Diagnostics | Former Employer | Company | Previous employer of David B. Patience where he served as CFO. |